Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the...
Vaccine
H1 Welcomes Former FDA Commissioner to Board of Directors, Acquires Ribbon Health, and Unveils 2025 Product Roadmap
Doubles down on its commitment to connecting the world with the right doctors and advancing healthcare innovation and inclusionNEW YORK,...
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study...
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective...
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option...
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/...
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today...
FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions
SILVER SPRING, Md., Jan. 6, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration issued draft guidance to provide recommendations...
New England Biolabs® Launches EM-seq™ v2, an updated kit for more sensitive detection of 5mC and 5hmC
This bisulfite-free method of methylation detection is updated with a faster, more streamlined workflow that enables highly sensitive methylation analysis...
FDA Issues Comprehensive Draft Guidance for Developers of Artificial Intelligence-Enabled Medical Devices
Guidance Shares Strategies to Address Transparency and Bias, while Providing Key Considerations and Recommendations on Product Design, Development and Documentation...
Why Diversity in Clinical Trials Is So Important
NORTHAMPTON, MA / ACCESSWIRE / January 6, 2025 / Clinical trials are essential for the development of health care products,...
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI),...
Defence Fortifies Patent Portfolio
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Genflow Biosciences PLC Announces 2024 Highlights
Genflow Biosciences Plc("Genflow" or "the Company")A Look Back at an Exciting 2024 LONDON, UNITED KINGDOM / ACCESSWIRE / January 6,...
Announcing the Launch of Relax VR-3: A Game-Changing Upgrade for Immersive Relaxation Experiences
SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Relax VR, a leader in multisensory virtual reality relaxation solutions, proudly announces the...
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO...
Defence Arranges Financing
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular...
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended...
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) --...